Skip to main content
SpringerLink
Log in

Benign Prostatic Hyperplasia

Practical Treatment Guidelines

  • Review Article
  • Disease Management
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Symptomatic benign prostatic hyperplasia (BPH) is a common condition in older men and has a significant impact on their daily lives. Transurethral resection of the prostate (TURP) or open prostatectomy are currently the most effective therapies for BPH. TURP is, however, associated with clinically significant adverse events in 20% of patients. Therefore, patients who need treatment for BPH based on the presence of symptoms should also be offered other therapy options.

Transurethral incision of the prostate is an effective therapy with minimal adverse effects in patients with a prostate not larger than 30g. Minimally invasive procedures, such as electrovaporisation, laser prostatectomy, transurethral needle ablation, high intensity focused ultrasound, transurethral microwave therapy and insertion of prostatic stents, can be performed instead of the standard surgical procedures. They are either performed as outpatient procedures or are associated with shorter durations of hospitalisation than TURP; in addition, they can also be performed in high risk patients. The efficacy of these procedures lies between that of TURP and medical therapy.

Medical therapy is becoming increasingly important in the treatment of patients with moderate symptoms of BPH. Both androgen-suppressing therapy and α-adrenoceptor blockade are well tolerated and effective modalities. Compared with placebo, both types of therapy produce improvements in maximum urinary flow rate and reductions in symptom scores of 15 to 20%. Finasteride, a potent 5α-reductase inhibitor, must be given for 6 months before its effectiveness in a given patient can be assessed, and for at least 12 months to achieve maximum prostate shrinkage and the full extent of its other beneficial effects. This may be perceived as a disadvantage when compared with the rapid relief afforded by surgery or α-blockade. The efficacy of finasteride is also dependent on prostate size; it should not be tried in patients with a prostate volume of <40ml. On the other hand, finasteride may reverse the progression of the disease process.

Of the α1-adrenoceptor antagonists, terazosin, doxazosin and tamsulosin can be administered once daily. In contrast, prazosin, alfuzosin and indoramin must be administered twice daily, which may have a negative impact on patient compliance. Because of its specificity for α1A-receptors, no dosage titration is needed when tamsulosin is used; in addition, in contrast with the other α-blockers used in BPH, tamsulosin lacks significant effects on blood pressure. On the other hand, nonselective α-blockers are preferable in hypertensive patients with BPH.

The final decision about the best treatment for a particular patient must take into account the patient’s preference after he has been informed of the different options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340–5

    PubMed  CAS  Google Scholar 

  2. Walsh PC. Human benign prostatic hyperplasia: etiological considerations. Prog Clin Biol Res 1984; 145: 1–25

    PubMed  CAS  Google Scholar 

  3. Oesterling JE. Benign prostatic hyperplasia: its natural history, epidemiologic characteristics, and surgical treatment. Arch Fam Med 1992; 1: 257–66

    PubMed  CAS  Google Scholar 

  4. Abrams P. New words for the old: lower urinary tract symptoms for ‘prostatism’: avoids spurious suggestion of diagnostic accuracy. BMJ 1994; 308: 929–30

    PubMed  CAS  Google Scholar 

  5. Abrams P. Managing lower urinary tract symptoms in older men. BMJ 1995; 310: 1113–7

    PubMed  CAS  Google Scholar 

  6. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495–507

    PubMed  CAS  Google Scholar 

  7. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71

    PubMed  CAS  Google Scholar 

  8. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 138: 979–83

    Google Scholar 

  9. Furuya S, Kumamoto Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836–9

    PubMed  CAS  Google Scholar 

  10. Andersen JT. α1-Blockers vs 5α-reductase inhibitors in benign prostatic hyperplasia: a comparative review. Drugs Aging 1995; 6: 388–96

    PubMed  CAS  Google Scholar 

  11. Andersen JT, Nordling J, Walter S. Prostatism: the correlation between symptoms, cystometric and urodynamic parameters. Scand J Urol Nephrol 1979; 13: 231–6

    Google Scholar 

  12. Nitti VW, Kim Y, Combs A. Correlation of the AU A symptoms index with urodynamics in patients with suspected benign prostatic hyperplasia. Neurourol Urodyn 1994; 13: 521–9

    PubMed  CAS  Google Scholar 

  13. Andersen JT. Prostatism: clinical, radiological and urodynamic aspects. Neurourol Urodyn 1982; 1: 241–93

    Google Scholar 

  14. McGuire EJ. The role of urodynamic investigation in the assessment of benign prostatic hypertrophy. J Urol 1992; 148: 1133–6

    PubMed  CAS  Google Scholar 

  15. Schäfer W. Analysis of active detrusor function during voiding with the bladder working function. Neurourol Urodyn 1991; 10: 19–35

    Google Scholar 

  16. Birkhoff JD, Wiederhorn AR, Hamilton ML, et al. Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 1976; 7: 48–52

    PubMed  CAS  Google Scholar 

  17. Ball AJ, Feneley RC, Abrams P. The natural history of untreated ‘prostatism’. Br J Urol 1981; 53: 613–6

    PubMed  CAS  Google Scholar 

  18. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595–600

    PubMed  CAS  Google Scholar 

  19. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631–7

    PubMed  CAS  Google Scholar 

  20. Arrighi HM, Metter EJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy. Urology 1991; 38 Suppl.: 4–8

    PubMed  CAS  Google Scholar 

  21. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment: quick reference guide for clinicians. AHCPR publication no. 94-0583. No. 8. Rockville (MD): Department of Health and Human Services, 1994

    Google Scholar 

  22. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. ? Engl J Med 1995; 332: 75–9

    CAS  Google Scholar 

  23. Fowler Jr FJ, Wennberg JE, Timothy RP, et al. Symptoms status and quality of life following prostatectomy. JAMA 1988; 259: 3018–22

    PubMed  Google Scholar 

  24. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243–7

    PubMed  CAS  Google Scholar 

  25. Holtgrewe HL, Mebust WK, Dowd JB, et al. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989; 141: 248–3

    PubMed  CAS  Google Scholar 

  26. Wennberg JE, Roos N, Sola L, et al. Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 1987; 257: 933–6

    PubMed  CAS  Google Scholar 

  27. Kuo HC, Chang SC, Hsu T. Predictive factors for successful surgical outcome of benign prostatic hypertrophy. Eur Urol 1993; 24: 12–6

    PubMed  CAS  Google Scholar 

  28. Trapasso JG, Irwin MB. Clinical outcome and reoperation after low-weight transurethral resection of the prostate. J Endourol 1994; 8: 165–9

    PubMed  CAS  Google Scholar 

  29. Agarwal M, Palmer JH, Mufti GR. Transurethral resection tor a large prostate — is it safe? Br J Urol 1993; 72: 318–21

    PubMed  CAS  Google Scholar 

  30. Keitzer WA, Cervantes L, Demaculangan A, et al. Transurethral incision of bladder neck for contracture. J Urol 1961; 86: 242–6

    PubMed  CAS  Google Scholar 

  31. Orandi A. Transurethral incision of the prostate. J Urol 1973; 110: 229–31

    PubMed  CAS  Google Scholar 

  32. Hellström P, Lukkarinen O, Kontturi M. Bladder neck incision or transurethral electroresection for the treatment of urinary obstruction caused by small prostate? A randomized urodynamic study. Scand J Urol Nephrol 1986; 20: 187–92

    PubMed  Google Scholar 

  33. Christensen MM, Aagaard J, Madsen PO. Transurethral resection versus transurethral incision of the prostate: a prospective randomized study. Urol Clin North Am 1990; 17: 621–30

    PubMed  CAS  Google Scholar 

  34. Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 1995; 332: 99–109

    PubMed  CAS  Google Scholar 

  35. Te AE, Kaplan SA. Electrovaporization of the prostate. Curr Opin Urol 1996; 6: 2–9

    Google Scholar 

  36. Hollander JB, Diokno AC. Prostatism: benign prostatic hyperplasia. Urol Clin North Am 1996; 23: 75–86

    PubMed  CAS  Google Scholar 

  37. Babayan RK. Transurethral ultrasound-guided laser-induced prostatectomy (TULIP): past, present, and future. J Endourol 1995; 9: 141–4

    PubMed  CAS  Google Scholar 

  38. McCullough DL. Laser prostatectomy: free beam and contact techniques. Curr Opin Urol 1996; 6: 10–3

    Google Scholar 

  39. Kabalin JM. Nd: YAG laser coagulation prostatectomy for benign prostatic hyperplasia: part I. Clinical outcomes. Afr J Urol 1995; 1: 112–8

    Google Scholar 

  40. Keoghane S, Cranston D, Lawrence K, et al. The Oxford laser trial: a prospective randomised controlled trial of contact vaporisation of the prostate versus TURP [abstract]. J Urol 1995; 153: 230A

    Google Scholar 

  41. Muschter R. Interstitial laser therapy. Curr Opin Urol 1996; 6: 33–8

    Google Scholar 

  42. TeSlaa E, Mooibroek JJ, DeReijke TM, et al. Laser treatment of the prostate using the Urolase fiber: the Dutch experience. J Urol 1996; 156: 420–5

    CAS  Google Scholar 

  43. Schatzl G, Madersbacher S, Marberger M. The postoperative morbidity of transurethral resection of the prostate (TUR/P) and of four minimally invasive treatment alternatives [abstract]. J Urol 1996; 155: 389A

    Google Scholar 

  44. Talja M, Tammela T, Petas A, et al. Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate — laser prostatectomy. J Urol 1995; 154: 2089–92

    PubMed  CAS  Google Scholar 

  45. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 1994; 45: 28–33

    Google Scholar 

  46. Issa MM, Oesterling JE. Transurethral needle ablation (TUNA™): an overview of radiofrequency thermal therapy for the treatment of benign prostatic hyperplasia. Curr Opin Urol 1996; 6: 20–7

    Google Scholar 

  47. Campo B, Bergamaschi F, Ordesi G, et al. TUNA in BPH patients: urodynamic assessment at 18th month followup [abstract]. J Urol 1996; 155: 371A

    Google Scholar 

  48. Rosario DJ, Woo HH, Byrne L, et al. 12 month follow-up of the safety and efficacy of TransUrethral Needle Ablation (TUNA™) [abstract]. J Urol 1996; 155: 705A

    Google Scholar 

  49. Heaton JPW. Radiofrequency thermal ablation of the prostate: the TUNA technique. Techniques Urol 1995; 1: 3–10

    CAS  Google Scholar 

  50. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate: a new treatment of benign prostatic hyperplasia using interstitial low-level radiofrequency energy. Curr Opin Urol 1996; 6: 35–8

    Google Scholar 

  51. Madersbacher S, Kratzik C, Susani M, et al. Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol 1994; 152: 1956–61

    PubMed  CAS  Google Scholar 

  52. Madersbacher S, Marberger M. High-intensity focused ultrasound for prostatic tissue ablation. Curr Opin Urol 1996; 6: 28–32

    Google Scholar 

  53. Dahlstrand C, Pettersson S. Resorbable stents can prevent retention after high energy TUMT for large symptomatic benign prostatic hyperplasia [abstract]. J Urol 1996; 155: 407A

    Google Scholar 

  54. Debruyne FMJ, Bloem FAG, de la Rosette JJMCH, et al. Transurethral thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT [abstract]. J Urol 1993; 149: 250A

    Google Scholar 

  55. Ogden CW, Reddy P, Johnson H, et al. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993; 341: 14–7

    PubMed  CAS  Google Scholar 

  56. Blute ML. Microwave thermotherapy for the treatment of benign prostatic hyperplasia. Semin Urol 1994; 12: 181–5

    PubMed  CAS  Google Scholar 

  57. Dahlstrand C, Waldén M, Geirssom G, et al. Transurethral microwave thermotherapy versus transurethral resection for BPH. In: Benign prostatic hyperplasia. Wiley-Liss Inc., 1994: 455–61

    Google Scholar 

  58. Perrin P, Devonec M, Houdelette P, et al. Transurethral microwave thermotherapy: high energy improves clinical results [abstract]. J Urol 1995; 153: 434A

    Google Scholar 

  59. Milroy E. Permanent prostate stents. J Endourol 1991; 5: 75–8

    Google Scholar 

  60. Williams G, Coulange C, Milroy EJG, et al. The Urolume, a permanently implanted prostatic stent for patients at high risk for surgery. Br J Urol 1993; 72: 335–40

    PubMed  CAS  Google Scholar 

  61. Parikh AM, Milroy EJG. Precautions and complications in the use of the Urolume Wallstent. Eur Urol 1995; 27: 1–7

    PubMed  CAS  Google Scholar 

  62. White JW. The results of double castration in hypertrophy of the prostate. Ann Surg 1895; 22: 1–80

    PubMed  CAS  Google Scholar 

  63. Cabot AT. The question for castration in enlarged prostate. Ann Surg 1896; 24: 265–309

    PubMed  CAS  Google Scholar 

  64. Schröder FH, Westerhof M, Bosch RJ, et al. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report of 6 cases. Eur Urol 1986; 12: 318–21

    Google Scholar 

  65. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone releasing-hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599–604

    PubMed  CAS  Google Scholar 

  66. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 359–64

    PubMed  CAS  Google Scholar 

  67. McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 661–70

    PubMed  CAS  Google Scholar 

  68. Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo-controlled study. J Urol 1975; 114: 564–8

    PubMed  CAS  Google Scholar 

  69. Stone NN, Clejan SJ. Response of prostate volume, prostatic-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia. J Androl 1991; 12: 376–80

    PubMed  CAS  Google Scholar 

  70. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 90–4

    PubMed  CAS  Google Scholar 

  71. Donkervoort T, Sterling AM, Ness JV, et al. Megestrol acetate in the treatment of benign prostatic hypertrophy. Urology 1975; 4: 580–7

    Google Scholar 

  72. Geller J, Nelson CG, Albert JD, et al. Effects of megestrol acetate on uroflow in patients with benign prostatic hyperplasia. Urology 1979; 14: 467–74

    PubMed  CAS  Google Scholar 

  73. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213–5

    PubMed  CAS  Google Scholar 

  74. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Ann Rev Biochem 1994; 63: 25–61

    PubMed  CAS  Google Scholar 

  75. Wilson JD, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isoenzyme expression. J Clin Invest 1993; 92: 577–87

    Google Scholar 

  76. Peterson RE, Imperato-McGinley J, Gautier T, et al. Pseudohermaphroditism due to steroid 5α-reductase deficiency. Am J Med 1977; 62: 170–91

    PubMed  CAS  Google Scholar 

  77. Bardin CW, Catterall JF. Testosterone: a major determinant of extragenital sexual dimorphism. Science 1981; 211: 1285–94

    PubMed  CAS  Google Scholar 

  78. Baum MJ, Vreeburg JTM. Copulation in castrated male rats following combined treatment with estradiol and dihydrotestosterone. Science 1973; 182: 283–5

    PubMed  CAS  Google Scholar 

  79. Wilson JD, Griffin JE, George FW. Sexual differentiation: early hormone synthesis and action. Biol Reprod 1980; 22: 9–17

    PubMed  CAS  Google Scholar 

  80. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isoenzyme expression. J Clin Invest 1993; 92: 903–7

    PubMed  CAS  Google Scholar 

  81. Brooks JR, Berman C, Primka RL, et al. 5α-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat. Steroids 1986; 47: 1–19

    PubMed  CAS  Google Scholar 

  82. Rasmusson GH, Reynolds GF, Steinberg NG, et al. Azasteroids: structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J Med Chem 1986; 29: 2298–315

    PubMed  CAS  Google Scholar 

  83. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in man with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91

    PubMed  CAS  Google Scholar 

  84. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–9

    Google Scholar 

  85. Boyarsky S, Jones G, Paulson DF, et al. A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. J Urol 1997; 68: 29–32

    Google Scholar 

  86. Stoner E, members of the Finasteride Study group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284–94

    PubMed  CAS  Google Scholar 

  87. Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience. Eur Urol 1995; 28: 305–9

    Google Scholar 

  88. Tammela TLJ, Kontturi MJ. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993; 149: 342–4

    PubMed  CAS  Google Scholar 

  89. Tammela TLJ, Kontturi MJ. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 1995; 154: 1466–9

    PubMed  CAS  Google Scholar 

  90. Lepor H, Williford WO, Barry MJ, et al. The efficacy of ter-azosin, finasteride, or both in benign prostatic hyperplasia. N Engl JMed 1996; 335: 533–9

    CAS  Google Scholar 

  91. Walsh PC. Treatment of benign prostatic hyperplasia. N Engl J Med 1996; 335: 586–7

    PubMed  CAS  Google Scholar 

  92. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405

    PubMed  CAS  Google Scholar 

  93. Drach GW, Layton TN, Binard WJ. Male peak urinary flow rate: relationships to volume voided and age. J Urol 1979; 122: 210–4

    PubMed  CAS  Google Scholar 

  94. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–9

    PubMed  CAS  Google Scholar 

  95. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986; 136: 1–4

    PubMed  CAS  Google Scholar 

  96. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostate capsule and bladder neck. Br J Urol 1975; 47: 193–202

    PubMed  CAS  Google Scholar 

  97. Lepor H, Shapiro E. Characterization of the alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol 1984; 132: 1226–9

    PubMed  CAS  Google Scholar 

  98. Shapiro E, Lepor H. Alpha2 adrenergic receptors in hyperplastic human prostate: identification and characterization using (3H)rauwolscine. J Urol 1986; 135: 1038–42

    PubMed  CAS  Google Scholar 

  99. Shapiro E, Hartanto V, Lepor H. The response to alpha-blockade in benign prostatic hyperplasia is related to the percent area density of prostatic smooth muscle. Prostate 1992; 21: 297–307

    PubMed  CAS  Google Scholar 

  100. Chappie CR. Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129–44

    Google Scholar 

  101. Ford APDW, Williams TJ, Blue DR, et al. Alpha-1-adrenoceptor classification: sharpening Occam’s razor. Trends Pharmacol Sci 1994; 15: 167–70

    PubMed  CAS  Google Scholar 

  102. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha-1-adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546–51

    PubMed  CAS  Google Scholar 

  103. Forray C, Bard JA, Wetzel JM, et al. The alpha-1-adrenergic receptor that mediates smooth muscle contraction in the human prostate has the pharmacological properties of the cloned human alpha-1c subtype. Mol Pharmacol 1994; 45: 703–8

    PubMed  CAS  Google Scholar 

  104. Chappie CR, Burt RP, Andersson PO, et al. Alpha-1-adrenoceptor subtypes in the human prostate. Br J Urol 1994; 74: 585–9

    Google Scholar 

  105. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923–34

    PubMed  CAS  Google Scholar 

  106. Narayan P, Indudhara R. Pharmacotherapy for benign prostatic hyperplasia. West J Med 1994; 161: 495–506

    PubMed  CAS  Google Scholar 

  107. Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction. Urology 1981; 17: 542–6

    PubMed  CAS  Google Scholar 

  108. Abrams P, Shah PJR, Stone R, et al. Bladder outlet obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527–30

    PubMed  CAS  Google Scholar 

  109. Hedlund H, Andersson K-E, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275–8

    PubMed  CAS  Google Scholar 

  110. Kirby RS, Coppinger SWC, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 60: 136–42

    PubMed  CAS  Google Scholar 

  111. Chappie CR, Stott M, Abrams PH, et al. A 12-week placebo-controlled study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285–94

    Google Scholar 

  112. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled, multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467–74

    PubMed  CAS  Google Scholar 

  113. Lloyd SN, Buckley JF, Chilton CP. Terazosin in the treatment of benign prostatic hyperplasia: a multicenter, placebo-controlled trial. Br J Urol 1992; 70: 17–21

    PubMed  Google Scholar 

  114. Brawer MK, Adams G, Epstein H, et al. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993; 2: 929–35

    PubMed  CAS  Google Scholar 

  115. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46–51

    PubMed  CAS  Google Scholar 

  116. Wilde MI, Fitton A, Sorkin EM. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3: 258–77

    PubMed  CAS  Google Scholar 

  117. Lepor H, for the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406–13

    PubMed  CAS  Google Scholar 

  118. Buzelin JM, Geffriaud-Ricouard C, Delauche-Cavallier, et al. A double-blind, placebo-controlled trial of the efficacy and safety of sustained-release alfuzosin in symptomatic benign prostatic hyperplasia [abstract]. J Urol 1995; 153: 274A

    Google Scholar 

  119. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–61

    PubMed  CAS  Google Scholar 

  120. Wilde MI, Fitton A, McTavish D. Alfuzosin: a review of its pharmacodynamic properties and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45: 410–29

    PubMed  CAS  Google Scholar 

  121. Teillac P, Delauche-Cavallier MC, Attali P, et al. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 79: 58–64

    Google Scholar 

  122. Buzelin JM, Herbert M, Blondin P, et al. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922–7

    PubMed  CAS  Google Scholar 

  123. Young RA, Brogden RN. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild to moderate hypertension. Drugs 1988; 355: 535–41

    Google Scholar 

  124. Kirby RS. Doxazosin: safety relative to other medical therapies for benign prostatic hyperplasia. Eur Urol 1996; 29Suppl. 1: 24–30

    Google Scholar 

  125. Lepor H, and the Multicenter Study Group. Long-term efficacy and safety of doxazosin for the treatment of benign prostatic hyperplasia. J Urol 1995; 153: 273A

    Google Scholar 

  126. Pool JL. Unique aspects of doxazosin: a third-generation alpha-blocker. Eur Urol 1996; 29Suppl. 1: 31–9

    Google Scholar 

  127. Christensen MM, Holme JB, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction. Scand J Urol Nephrol 1993; 27: 39–44

    PubMed  CAS  Google Scholar 

  128. Holme JB, Christensen MM, Rasmussen PC, et al. 29-Week doxazosin treatment in patients with symptomatic prostatic hyperplasia. Scand J Urol Nephrol 1994; 28: 77–82

    Google Scholar 

  129. Chapple CR, Carter P, Christmas TJ, et al. A three-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50–6

    PubMed  CAS  Google Scholar 

  130. Scott MA, Abrams P. Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol 1991; 67: 499–501

    Google Scholar 

  131. Michel MC, Büscher R, Kerker J, et al. α1-Adrenoceptor subtype affinities of drugs for treatment of prostatic hypertrophy: evidence of heterogeneity of chloroethylclonidine-resistant rat renal α1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 385–95

    PubMed  CAS  Google Scholar 

  132. Foglar R, Shibita K, Horie K, et al. Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995; 288: 201–7

    PubMed  CAS  Google Scholar 

  133. Abrams P, Schulman CC, Vaage S, et al. Tamsulosin, a selective α1-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br J Urol 1995; 76: 325–36

    PubMed  CAS  Google Scholar 

  134. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155–67

    PubMed  CAS  Google Scholar 

  135. Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145–54

    PubMed  CAS  Google Scholar 

  136. Lepor H, for the Tamsulosin Investigator Group. Clinical evaluation of tamsulosin, a prostate selective alpha-lc-antagonist [abstract]. J Urol 1995; 153: 274A.

    Google Scholar 

  137. Starkey LP, Yasakawa K, Trenga C, et al. Study of possible pharmacodynamic interaction between tamsulosin and nifedipine in subjects with essential hypertension [abstract 45]. J Clin Pharmacol 1994; 34: 1019

    Google Scholar 

  138. Starkey LP, Trenga C, Miyazawa Y, et al. Lack of clinical interactions between tamsulosin and enalapril [abstract PII-11]. Clin Pharmacol Ther 1995; 57: 166

    Google Scholar 

  139. Roos NP, Wennberg JE, Malenka DJ, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320: 1120–4

    PubMed  CAS  Google Scholar 

  140. Concato J, Horowitz RI, Feinstein AR, et al. Problems of comorbidity in mortality after prostatectomy. JAMA 1992; 267: 1077–86

    PubMed  CAS  Google Scholar 

  141. Koshiba K, Egawa S, Ohori M, et al. Does transurethral resection of the prostate pose a risk to life? 22-year outcome. J Urol 1995; 153: 1506–9

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Tampere University Hospital, P.O. Box 2000, FIN-33521, Tampere, Finland

    Teuvo Tammela

Authors
  1. Teuvo Tammela
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teuvo Tammela.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tammela, T. Benign Prostatic Hyperplasia. Drugs & Aging 10, 349–366 (1997). https://doi.org/10.2165/00002512-199710050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710050-00004

Keywords

Search

Navigation